Pharmacoeconomics of dabigatran etexilate for prevention of thromboembolism after joint replacement surgery

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 11, Issue 1, 2011, Pages 9-25

  Wolowacz, Sorrel E ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

economics; primary prevention; review; thromboembolism; total hip replacement; total knee replacement

Indexed keywords

DABIGATRAN ETEXILATE; ENOXAPARIN; FONDAPARINUX; PLACEBO; RIVAROXABAN; WARFARIN;

ARTICLE; BLEEDING; CANADA; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ETHNIC DIFFERENCE; EVENING DOSAGE; EVIDENCE BASED MEDICINE; GERMANY; HIP ARTHROPLASTY; HUMAN; JOINT PROSTHESIS; KNEE ARTHROPLASTY; PORTUGAL; QUALITY ADJUSTED LIFE YEAR; RECOMMENDED DRUG DOSE; SPAIN; SYSTEMATIC REVIEW; THROMBOSIS PREVENTION; TREATMENT DURATION; UNITED KINGDOM; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; BENZIMIDAZOLES; ECONOMICS, PHARMACEUTICAL; HUMANS; PYRIDINES; VENOUS THROMBOEMBOLISM;

EID: 79952163512     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.10.89     Document Type: Article

References (88)

1. Arcelus JI, Monreal M, Caprini JA et al.; the RIETE Investigators. Clinical presentation and time-course of postoperative venous thromboembolism: results from the RIETE Registry. Thromb. Haemost. 99(3), 546-551 (2008). (Pubitemid 351549291)
2. Prandoni P, Lensing AW, Prins MR. Long-term outcomes after deep venous thrombosis of the lower extremities. Vasc. Med. 3(1), 57-60 (1998). (Pubitemid 28267463)
3. Tapson VF, Hyers TM, Waldo AL et al. Antithrombotic therapy practices in US hospitals in an era of practice guidelines. Arch. Intern. Med. 165, 1458-1464 (2005). (Pubitemid 41058025)
4. Geerts WH, Bergqvist D, Pineo GF et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133, 381S-453S (2008). (Pubitemid 351894916)
5. ODonnell M, Linkins LA, Kearon C et al. Reduction of out-of-hospital symptomatic venous thromboembolism by extended thromboprophylaxis with low-molecular-weight heparin following elective hip arthroplasty: a systematic review. Arch. Intern. Med. 163(11), 1362-1366 (2003). (Pubitemid 36676203)
6. Anderson FA Jr, Hirsh J, White K et al. Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996-2001: findings from the Hip and Knee Registry. Chest 124, 349S-356S (2003). (Pubitemid 38005461)
7. Stassen JM, Hauel NH, Nar H et al. Identification and in vitro characterization of BIBR 953 ZW, a novel synthetic low molecular weight direct thrombin inhibitor. Presented at: The 28th Congress of the International Society on Thrombosis and Haemostasis. Paris, France, 6-12 July 2001.
8. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin. Pharmacokinet. 47(5), 285-295 (2008). (Pubitemid 351508116)
9. Eriksson BI, Dahl OE, Rosencher N et al.; the RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J. Thromb. Haemost. 5(11), 2178-2185 (2007). (Pubitemid 47617868)
10. Ginsberg JS, Davidson BL, Comp PC et al. The oral thrombin inhibitor dabigatran etexilate vs the North American enoxaparin regimen for the prevention of venous thromboembolism after knee arthroplasty surgery. J. Arthroplasty 24(1), 1-9 (2008).
11. Eriksson BI, Dahl OE, Rosencher N et al.; the RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370(9591), 949-956 (2007). (Pubitemid 47393577)
12. Eriksson B, Dahl OE, Kurth AA et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty: the RE-NOVATE II randomised trial. Presented at: 21st International Congress on Thrombosis. Milan, Italy, 6-9 July 2010.
13. Huo M, Eriksson B, Dahl O et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary hip arthroplasty: the RE-NOVATE II randomized trial. Presented at: 15th Congress of the European Hematology Association. Barcelona, Spain, 10-13 June 2010.
14. Bellamy L, Rosencher N, Eriksson BI. Adherence to a new oral anticoagulant treatment prescription: dabigatran etexilate. Patient Prefer. Adherence 3, 173-177 (2009).
15. Wilke T. Patient preferences for an oral anticoagulant after major orthopedic surgery. Results of a German Survey. Patient 2(1), 39-49 (2009).
16. Schulman S, Kearon C, Kakkar AK et al.; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N. Engl. J. Med. 361(24), 2342-2352 (2009).
17. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361, 1-13 (2009).
18. Eriksson BI, Dahl OE, Rosencher N et al.; the RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J. Thromb. Haemost. 5(11), 2178-2185 (2007). (Pubitemid 47617868)
19. Eriksson BI, Dahl OE, Rosencher N et al.; the RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370(9591), 949-956 (2007). (Pubitemid 47393577)
20. Friedman RJ, Dahl OE, Rosencher N et al. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb. Res. 126(3), 175-182 (2010).
21. Wolowacz SE, Roskell NS, Plumb JM et al. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty: a meta-analysis. Thromb. Haemost. 101(1), 77-85 (2009).
22. Stangier J, Rathgen K, Stahle H et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br. J. Clin. Pharmacol. 64, 292-303 (2007). (Pubitemid 47283865)
23. Blech S, Ebner T, Ludwig-Schwellinger E et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab. Dispos. 36, 386-399 (2008). (Pubitemid 351185753)
24. Ezekowitz MD, Reilly P, Nehmiz G et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO study). Am. J. Cardiol. 100, 1419-1426 (2007). (Pubitemid 47576022)
25. Busby LT, Weyman A, Rodgers GM. Excessive anticoagulation in patients with mild renal insufficiency receiving long-term therapeutic enoxaparin. Am. J. Hematol. 67, 54-56 (2001). (Pubitemid 32336706)
26. Thorevska N, Amoateng-Adjepong Y, Sabahi R et al. Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs enoxaparin. Chest 125, 856-863 (2004). (Pubitemid 38367274)
27. Dahl OE, Kurth AA, Rosencher N et al. Efficacy and safety profile of dabigatran etexilate for the prevention of venous thromboembolism in moderately renally impaired patients after total knee or hip replacement surgery. Blood 112(11), 361 (2008) (Abstract 981).
28. Dahl OE, Kurth AA, Rosencher N et al. Efficacy and safety profile of dabigatran etexilate compared with enoxaparin in primary venous thromboembolism prevention after total knee or hip replacement surgery in patients over 75 years. Blood 112(11), 167 (2008) (Abstract 437).
29. Fuji T, Fuijita S, Ujihira T et al. Dabigatran etexilate prevents venous thromboembolism after total knee arthroplasty in Japanese patients, with a safety profile comparable to placebo. J. Arthroplasty 25(8), 1267-1274 (2009).
30. Ivanovic N, Beinema M, Brouwers JR et al. Thromboprophylaxis in total hip-replacement surgery in Europe: acenocoumarol, fondaparinux, dabigatran and rivaroxban (brief record). Expert Rev. Pharmacoeconomics Outcomes Res. 7, 49-58 (2007).
31. Martins HS, Scalabrini-Neto A, Velasco IT. Dabigatran versus enoxaparin after total hip replacement. Lancet 370(9604), 2002-2003 (2007). (Pubitemid 350236332)
32. Holmes M, Carroll C, Papaioannou D. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal. Health Technol. Assess. 13(Suppl. 2), 55-62 (2009).
33. Wolowacz SE, Roskell NS, Maciver F et al. Economic analysis of dabigatran etexilate for the prevention of venous thromboembolism following total knee and hip replacement surgery. Clin. Ther. 31(1), 1-19 (2009).
34. Bouee S, Zufferey P, Fagnani F. Budget impact analysis of Pradaxa thromboprophylaxis after total hip or total knee replacement. Therapie 64(4), 249-257 (2009).
35. Wilke T, Neumann K, Klapper U et al. Oral anticoagulation after major hip or knee replacement surgery: a process-driven managerial pharmacoeconomic analysis in German hospitals. Orthopade 37(5), 448-456 (2008).
36. McCullagh L, Tilson L, Walsh C, Barry M. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting. Pharmacoeconomics 27(10), 829-846 (2009).
37. Boersma C, Kappelhoff BS, Postma MJ. Dabigatran etexilate is cost-saving for the primary prevention of venous thromboembolic events following major orthopaedic surgery in The Netherlands. Presented at: The 12th Annual European Congress of ISPOR. Paris, France, 24-27 October 2009.
38. Boersma C, Kappelhoff BS, Postma MJ. Dabigatran etexilate is cost-saving for the primary prevention of venous thromboembolic events following major orthopaedic surgery in The Netherlands. Presented at: 51st Annual Meeting of the American Society of Hematology. New Orleans, LA, USA, 5-8 December 2009.
39. Wolowacz SE, Hess N, Brennan VK et al. Cost-effectiveness of venous thromboembolism prophylaxis in total hip and knee replacement surgery: the evolving application of health economic modelling over 20 years. Curr. Med. Res. Opin. 24(10), 2993-3006 (2008).
40. Watts AC, Howie CR, Simpson AH. Assessment of a self-administration protocol for extended subcutaneous thromboprophylaxis in lower limb arthroplasty. J. Bone Joint Surg. Br. 88-B, 107-110 (2006). (Pubitemid 43125324)
41. Botteman MF, Caprini J, Stephens JM et al. Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United States. Clin. Ther. 24(11), 1960-1986 (2002). (Pubitemid 35440962)
42. Ingelgard A, Hedner E, Stigendal J et al. Patient-reported outcomes in patients with deep vein thrombosis treated with warfarin. Presented at: 17th International Congress on Thrombosis. Bologna, Italy, 26-30 October 2002.
43. Robinson A, Thomson R, Parkin D et al. How patients with atrial fibrillation value different health outcomes: a standard gamble study. J. Health Serv. Res. Policy 6(2), 92-98 (2001). (Pubitemid 32410452)
44. NICE. Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults. Technology appraisal guidance 157. National Institute for Health and Clinical Excellence, London, UK (2008).
45. Scottish Medicines Consortium. Drug Advice: Dabigatran Etexilate, 75 mg and 110 mg Hard Capsules (Pradaxa). Scottish Medicines Consortium, Glasgow, Scotland (2008).
46. Wolowacz SE, Roskell NS, Plumb JM et al. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement. Thromb. Haemost. 103(2), 360-371 (2009).
47. Bradley-Kennedy C, Wolowacz SE, Roskell NS, Plumb JM. Cost-effectiveness of dabigatran etexilate in Canada for the primary prevention of venous thromboembolism (VTE) in patients undergoing total hip replacement surgery (THR). Presented at: 22nd International Congress of the International Society on Thrombosis and Haemostasis. Boston, MA, USA, 11-16 July 2009.
48. Bradley-Kennedy C, Wolowacz SE, Roskell NS, Plumb JM. Cost-effectiveness of dabigatran etexilate in Canada for the primary prevention of venous thromboembolism (VTE) in patients undergoing total knee replacement surgery (TKR). Presented at: 22nd International Congress of the International Society on Thrombosis and Haemostasis. Boston, MA, USA, 11-16 July 2009.
49. Canadian Joint Replacement Registry. 2007 Annual Report - Hip and Knee Replacements in Canada. Canadian Institute for Health Information, Ottawa, Canada (2008).
50. Canadian Agency for Drugs and Technologies in Health. Guidelines for the Economic Evaluation of Health Technologies: Canada (3rd Edition). Canadian Agency for Drugs and Technologies in Health, Ottawa, Canada (2006).
51. Skedgel C, Goeree R, Pleasance S et al. The cost-effectiveness of extended-duration antithrombotic prophylaxis after total hip arthroplasty. J. Bone Joint Surg. Am. 89, 819-828 (2007). (Pubitemid 46564288)
52. Bradley-Kennedy C, Wolowacz SE, Roskell NS, Clemens A. Cost-effectiveness of dabigatran etexilate 150 mg in Canada for the prevention of venous thromboembolism in patients undergoing total knee or hip arthroplasty that have moderate impairment of renal function. Presented at: 22nd International Congress of the International Society on Thrombosis and Haemostasis. Boston, MA, USA, 11-16 July 2009.
53. González-Rojas N, Vieta A, Wolowacz SE. Economic analysis of dabigatran etexilate for the primary prevention of venous thromboembolism in patients undergoing total hip or knee replacement surgery (Spain). Pharmacoeconomics 6(4), 126-145 (2009).
54. González-Rojas N, Vieta A, Monreal M, Wolowacz SE. Economic analysis of dabigatran etexilate for the primary prevention of venous thromboembolism following total hip or knee replacement in Spain. Presented at: 12th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research. Paris, France, 24-27 October 2009.
55. González-Rojas N, Monreal M, Wolowacz SE. Economic evaluation of dabigatran etexilate for the primary prevention of venous thromboembolism after total knee and hip replacement surgery. Presented at: Spanish Society of Hospital Pharmacists. Zaragoza, Spain, 22-25 September 2009.
56. Mateus C, Wolowacz S, Pereira J. Cost-effectiveness of dabigatran etexilate for the primary prevention of venous thromboembolism in total hip and knee replacement in Portugal. Presented at: 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research. Orlando, FL, USA, 16-20 May 2009.
57. Sutton A, Ades AE, Cooper N et al. Use of indirect and mixed treatment comparisons for technology assessment. Pharmacoeconomics 26(9), 753-767 (2008).
58. Song F, Altman DG, Glenny AM et al. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. Br. Med. J. 326(7387), 472-475 (2003). (Pubitemid 36269627)
59. Plumb JM, Clemens A, Monz BU. Cost-effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review. Pharmacoeconomics 28(9), 781-782; author reply 782-784, 784-785 (2010).
60. Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J. Thromb. Haemost. 5(12), 2368-2375 (2007). (Pubitemid 350154345)
61. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N. Engl. J. Med. 361(6), 594-604 (2009).
62. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P; ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 375(9717), 807-815 (2010).
63. Turpie AG, Bauer KA, Davidson BL et al. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb. Haemost. 101(1), 68-76 (2009).
64. Eriksson BI, Turpie AG, Lassen MR et al.; ONYX-2 Study Group. Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2). J. Thromb. Haemost. 8(4), 714-721 (2010).
65. Eriksson BI, Dahl OE, Buller HR et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J. Thromb. Haemost. 3, 103-111 (2005). (Pubitemid 41647122)
66. Wolowacz S, Roskell N, Maciver F et al. Cost-effectiveness of dabigatran etexilate for the primary prevention of venous thromboembolism in patients undergoing total hip or total knee replacement surgery. Presented at: 11th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research. Athens, Greece, 8-11 November 2008.
67. Wolowacz SE, Roskell NS, Plumb JM et al. Cost-effectiveness of dabigatran etexilate 150 mg for the prevention of venous thromboembolism in elderly patients undergoing total hip or knee arthroplasty. Presented at: 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research. Orlando, FL, USA, 16-20 May 2009.
68. Wolowacz SE, Roskell NS, Plumb JM et al. Cost-effectiveness of dabigatran etexilate 150 mg for the prevention of venous thromboembolism in patients undergoing total hip or knee arthroplasty that have moderate impairment of renal function. Presented at: 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research. Orlando, FL, USA, 16-20 May 2009.
69. National Joint Registry for England and Wales: 4th Annual Clinical Report www.njrcentre.org.uk/NjrCentre/ LinkClick.aspx?fileticket=8ym2zOoRfvw %3d&tabid=86&mid=523
70. National Institute for Health and Clinical Excellence. Clinical guidelines CG46: Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in inpatients undergoing surgery http://guidance.nice.org.uk/CG46
71. Pradaxa 110 mg hard capsules. Summary of product characteristics http://emc.medicines.org.uk/ medicine/20760/SPC/ Pradaxa+110+mg+hard+capsules
72. National Institute for Health and Clinical Excellence. Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults. Technology appraisal guidance 157 www.nice.org.uk/nicemedia/pdf/ TA157Guidance.pdf
73. Scottish Medicines Consortium. Dabigatran etexilate, 75mg and 110mg hard capsules (Pradaxa). No. 466/08 www.scottishmedicines.org.uk/smc/files/ dabigatran%20etexilate%20Pradaxa%20 FINAL%20May%202008%20for%20 website.pdf
74. National Centre for Pharmacoeconomics Economic evaluation on the cost effectiveness of dabigatran etexilate (Pradaxa®) for the primary prevention of venous thromboembolic events in adult patients who have undergone total hip replacement or total knee replacement surgery www.ncpe.ie/document. php?cid=33&sid=110&docid=159
75. Pharmaceutical Benefits Advisory Committee. Public summary document. Dabigatran etexilate mesilate, capsules, 75 mg and 110 mg (base), Pradaxa® www.health.gov.au/internet/main/ publishing.nsf/Content/pbac-psd- Dabigatran-nov09
76. Het College voor zorgverzekeringen (CVZ). Advies dabigatran (Pradaxa) www.cvz.nl/binaries/live/CVZ-Internet/ hst-content/nl/documenten/ rapporten/2009/ rpt0909+dabigatran+pradaxa.pdf
77. The Dental and Pharmaceutical Benefits Agency, TLV. Pradaxa for thromboprophylaxis www.tlv.se/Upload/Beslut-2008/ bes080930-pradaxa.pdf
78. Family Practice Notebook: Creatinine clearance www.fpnotebook.com/Renal/ Lab/ CrtnClrnc.htm
79. Arixtra 2.5 mg/0.5 ml solution for injection, pre-filled syringe. Summary of product characteristics http://emc.medicines.org.uk/ medicine/15123/SPC/ Arixtra+2.5mg+0.5ml +solution+for+injection%2c+pre-filled+syringe
80. The Royal College of Surgeons in England, National Collaborating Centre for Acute Care. Venous thromboembolism guideline. Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in inpatients undergoing surgery www.rcseng.ac.uk/publications/docs/ venous-thrombo.html
81. Clexane pre-filled syringes and multi-dose vial. Summary of product characteristics http://emc.medicines.org.uk/ medicine/12847/SPC/Clexane+Pre- Filled+Syringes+and+Multi-dose+Vial
82. Ontario Health Insurance. Schedule of benefits for physician services under the Health Insurance Act www.health.gov.on.ca/english/providers/ program/ohip/sob/physserv/ physserv-mn.html
83. Ontario Drug Benefit Formulary, Comparative Drug Index, e-formulary. Version 201. Effective July 16, 2010 www.healthinfo.moh.gov.on.ca/formulary/ index.jsp
84. Anderson DR, OBrien BJ, Nagpal S et al. Economic evaluation comparing low molecular weight heparin with other modalities for the prevention of deep vein thrombosis and pulmonary embolism following total hip or knee arthroplasty. Canadian Coordinating Office for Health Technology Assessment (CCOHTA), Ottawa, Canada (1998) http://cadth.ca/media/pdf/lmwh-tr-e.pdf
85. Canadian Agency for Drug Technologies in Health, Common Drug Review. Dabigatran etexilate, 2009 www.cadth.ca/media/cdr/complete/cdr- complete-Pradax-March-3-2009.pdf
86. National Institute for Health and Clinical Excellence. Venous thromboembolism- dabigatran: final appraisal determination www.nice.org.uk/ guidance/index. jsp?action=download&o=41440
87. IPHA Medicines Compendium (online). Bayer Limited. Xarelto. Summary of product characteristics www.medicines.ie/medicine/13755/ SPC/Xarelto
88. Committee for Proprietary Medicinal Products. Points to consider on clinical investigation of medicinal products for prophylaxis of intra- and post-operative venous thromboembolic risk www.emea.europa.eu/pdfs/human/ ewp/070798en.pdf